A world of possibilities
Navigating life sciences and medtech to the extraordinary—driven by creativity, curiosity, and the courage to build a fulfilling journey.
-
Prime Editing: A New Genome Engineering Paradigm and Its Intellectual Property Implications
Prime editing represents a significant technological advance in genome engineering, combining the programmability of CRISPR systems with the precision of reverse transcription–mediated DNA synthesis. First reported in 2019 and refined through subsequent generations (PE2, PE3,…
-
Life Biosciences Patent Analysis: Partial Epigenetic Reprogramming
This report provides a comprehensive analysis of Life Biosciences’ key patent, US Patent No. 12,252,518, including claim summaries, plain-language interpretation, comparison with competitors (Turn Bio, NewLimit, Altos Labs), mapping of their partial epigenetic reprogramming (PER)…
-
Anti‑CEACAM5 antibody drug conjugates
Publication Number: US 20250321446 A1Filing Date: February 26, 2025 (earliest‑filed application)Publication Date: January 13, 2026 (publication of the granted patent) Assignee / Applicant: Bristol‑Myers Squibb Company What This Covers This patent relates to antibody‑drug conjugates (ADCs) targeting CEACAM5 (carcinoembryonic antigen‑related cell adhesion molecule 5) — a cell surface protein frequently…
BioTech IP Review 